Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-855-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
As discussed in the read across rationale attached in section 13, the citrate part of ammonium dihydrogen citrate is not considered relevant for repeated dose toxicity, as little or no effects are expected after repeated exposure up to high doses. For the ammonium part, a chronic feeding study with ammonium sulfate is used as key study. Based on this chronic toxicity study, the NOAEL was found to be 0.1% in feed, which was calculated to correlate to 256 mg/kg bw/day (males) and 284 mg/kg bw/day (females). The corresponding NOAEL was calculated to be 1255 mg/kg bw/day for ammonium dihydrogen citrate in water (≤ 55% ammonium dihydrogen citrate and ≥ 45% water).
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- The rationale to read across the data is attached in Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No obvious findings were observed.
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality was found in any groups throughout the treatment period.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No test substance-related change in the body weights was found.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No significant test substance-related change in the food intake was found. A tendency for increased food intake was noted in high dose males.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No significant variation was found in erythrocytic parameters and platelet count among the groups. Some slight changes were found in white blood cell count parameters (reticulocyte count was increased compared to control with -62.5% and 29.1% for the groups exposed to 0.1 and 0.6, respectively (high dose group was unaltered compared to control), white blood cell count decreased with -13.7%, -11% and -4.2% for the groups exposed to 0.1, 0.6 and 3.0%, respectively). Since there was no dose-relation these effects were considered to be incidental.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No dose-related alteration was found in any of the serum biochemical parameters. A slight increase was seen for T-Bil for the groups exposed to 0.1 and 0.6% (from 0.1 mg/dL (controls) to 0.2 (0.1% group) and 0.3 mg/dL (0.6% group)), however the high dose group had the same level as the controls. Similar pattern was seen for aspartate transaminase, alanine transaminase and alkaline phosphatase (aspartate transaminase: +23.9% and +52.3%; alanine transaminase: +43.6% and +76.4%; alkaline phosphatase: 10.5% and 18.1% for the groups exposed to 0.1% and 0.6%, respectivley). Also for these parameters, the high dose group showed same levels as the controls. In anbsence of a dose-relationship of the effects these results were considered non-adverse.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Kidney weights were increased at 3.0% in both sexes (in males: +11.2% (absolute) and +10% (relative); females: 10.5% (relative)). No changes compared to controls were found in the other organs of exposed animals.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no obvious macroscopic findings in any of the groups.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- In the high dose group, 4/10 males were found to have focal necrosis in the liver (1/10 in conrols). In females, bile duct prolifereation was seen in 3/10 high dose rats (not seen in controls, and 9/10 high dose rats had altered hepatocellular foci (also seen in 7/10 control females).
- Histopathological findings: neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A malignant pheochromocytoma of the adrenal in the male 3.0% group, two adenomas in the anterior pituitary in females of the 3.0% group (none found in control groups). These were considered coincidental findings.
- Dose descriptor:
- NOAEL
- Effect level:
- 810 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks:
- ammonium dihydrogen citrate (recalculated value; pure substance)
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 255 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks:
- ammonium dihydrogen citrate in water (recalculated value; ≤ 55% ammonium dihydrogen citrate and ≥ 45% water)
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 3 other: %
- System:
- hepatobiliary
- Organ:
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Conclusions:
- Based on a chronic toxicity study in rats with ammonium sulphate, the NOAEL was found to be 0.1% in feed, which was calculated to correlate to 256 mg/kg bw/day (males) and 284 mg/kg bw/day (females). This value is read across to ammonium dihydrogen citrate in water (see rationale section 13). The corresponding NOAEL was calculated to be 1255 mg/kg bw/day for ammonium dihydrogen citrate in water (≤ 55% ammonium dihydrogen citrate and ≥ 45% water).
- Executive summary:
A chronic toxicity study was performed with ammonium sulphate in male and female rats (10/sex/group), with exposure through feed at 0%, 0.1%, 0.6% and 3.0%. During the treatment period, clinical signs and mortality were observed daily, and body weight and food consumption were recorded every 2 weeks until week 10 and every 5 weeks thereafter. After sacrifice, hematological examinations and serum biochemistry were performed. Full necropsy was done (including organ weights) and histopathology was performed on controls and high dose groups. No effects were found on survival rate, body weights, and hematological, serum biochemical or histopathological parameters at any dose levels in the chronic toxicity study. Kidney weights were increased at 3.0% in both sexes (in males: +11.2% (absolute) and +10% (relative); females: 10.5% (relative)). No changes compared to controls were found in the other organs of exposed animals. In the high dose group, 4/10 males were found to have focal necrosis in the liver (1/10 in conrols). In females, bile duct prolifereation was seen in 3/10 high dose rats (not seen in controls, and 9/10 high dose rats had altered hepatocellular foci (also seen in 7/10 control females). Based on these results, the NOAEL was found to be 0.1% in feed, which was calculated to correlate to 256 mg/kg bw/day (males) and 284 mg/kg bw/day (females). This value is read across to ammonium dihydrogen citrate in water (see rationale section 13). The corresponding NOAEL was calculated to be 1255 mg/kg bw/day for ammonium dihydrogen citrate in water (≤ 55% ammonium dihydrogen citrate and ≥ 45% water).
Reference
The actual daily intake of the test substance (ammonium sulfate) was calculated to be 42, 256 and 1527 mg/kg bw/day for males and 48, 284 and 1490 mg/kg bw/day for females.
In order to adjust this value from the source chemical (ammonium sulfate) to the target chemical, the following calculation is used:
Based on a molecular weight of ammonium sulfate (MW=132.14), the ammonium part (2 NH4+, MW=36.08) has a weight percentage of 27.3%. Therefore, the adjusted NOAEL for the ammonium ion (NH4+) is calculated to be 69.9 mg/kg bw/day (256 mg/kg bw/day * 0.273)
Based on a molecular weight of the ammonium dihydrogen citrate (MW=209.15), the ammonium ion (MW=18.04) has a weight percentage of 8.63%. Therefore, the adjusted NOAEL for ammonium dihydrogen citrate is calculated to be 810 mg/kg bw/day ((69.9 mg/kg bw/day/ 8.63)*100).
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 1 255 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- The study used is considered reliable (Klimisch 2).
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the current data-set, the substance is not classified for adverse effects after repeated exposure according to Regulation (EC) No. 1272/2008 and its amendments.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.